April 18, 2019
Timothy Schroeder, CEO of CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization, will chair a panel at the Alliance for Regenerative Medicine (ARM) Cell and Gene Meeting on the Mediterranean in Barcelona, Spain. The panel is titled, "European Clinical Trials in a Global Context" and will be held on Wednesday, April 23. The panel discussions will focus on carrying out clinical trials with advanced therapy medicinal products in Europe, challenges inherent to the process, and possible ways to accelerate clinical trial authorizations. CTI is also a sponsor of the meeting.
"We are privileged to be a part of the ARM Cell and Gene Meeting on the Mediterranean, both as part of the panel and as a sponsor of the meeting," remarks Schroeder. "We believe that diagnosis and treatment paradigms will change dramatically in the near future based on the advances fostered in and furthered by the Alliance's meetings around the world."
ARM is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.
CTI has contributed to one of the first approvals in the cell and gene therapy space and has been actively working with cell and gene therapies since nearly the advent of the technology, making them one of the industry's experts in regenerative medicine. CTI has been a supporter of the Alliance for Regenerative Medicine for many years, most recently sponsoring and chairing a panel at the ARM Cell and Gene Meeting on the Mesa in La Jolla, CA in October 2018.
Timothy Schroeder, CEO and Founder of CTI, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which in one of the 20 largest CROs in the world and has supported more than 100 drug and device approvals, currently works on behalf of more than 200 global pharmaceutical and biotechnology companies. Prior to founding CTI, Tim held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995. Tim is currently a board member for over a dozen corporate and non-profit organizations, including Xavier University, which he attended. Tim was named as an EY Entrepreneur of the Year in 2015, as Top Leader by the Enquirer Media in 2016, and as Deal Maker of the Year in 2017 by the Association for Corporate Growth.